These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 18353438

  • 1. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.
    Nagashima H, Tezuka T, Tsuchida W, Maeda H, Kohroki J, Masuho Y.
    Mol Immunol; 2008 May; 45(10):2752-63. PubMed ID: 18353438
    [Abstract] [Full Text] [Related]

  • 2. [Enhancement of antibody-dependent cellular cytotoxicity by tandem Fc multimerization].
    Nagashima H, Masuho Y.
    Yakugaku Zasshi; 2010 Jan; 130(1):49-54. PubMed ID: 20046065
    [Abstract] [Full Text] [Related]

  • 3. Enhanced antibody-dependent cellular phagocytosis by chimeric monoclonal antibodies with tandemly repeated Fc domains.
    Nagashima H, Ootsubo M, Fukazawa M, Motoi S, Konakahara S, Masuho Y.
    J Biosci Bioeng; 2011 Apr; 111(4):391-6. PubMed ID: 21215693
    [Abstract] [Full Text] [Related]

  • 4. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M.
    Clin Cancer Res; 2006 May 01; 12(9):2879-87. PubMed ID: 16675584
    [Abstract] [Full Text] [Related]

  • 5. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S.
    Cancer Res; 2007 Sep 15; 67(18):8882-90. PubMed ID: 17875730
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [Abstract] [Full Text] [Related]

  • 7. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
    Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M.
    Biotechnol Bioeng; 2001 Aug 20; 74(4):288-94. PubMed ID: 11410853
    [Abstract] [Full Text] [Related]

  • 8. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths.
    Shan D, Press OW, Tsu TT, Hayden MS, Ledbetter JA.
    J Immunol; 1999 Jun 01; 162(11):6589-95. PubMed ID: 10352275
    [Abstract] [Full Text] [Related]

  • 9. Mapping epitopes of human Fc gamma RII (CDw32) with monoclonal antibodies and recombinant receptors.
    Ierino FL, Hulett MD, McKenzie IF, Hogarth PM.
    J Immunol; 1993 Mar 01; 150(5):1794-803. PubMed ID: 7679695
    [Abstract] [Full Text] [Related]

  • 10. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.
    J Immunol Methods; 2011 Oct 28; 373(1-2):67-78. PubMed ID: 21855548
    [Abstract] [Full Text] [Related]

  • 11. Cleavage of the interchain disulfide bonds in rituximab increases its affinity for FcγRIIIA.
    Suzuki M, Yamanoi A, Machino Y, Kobayashi E, Fukuchi K, Tsukimoto M, Kojima S, Kohroki J, Akimoto K, Masuho Y.
    Biochem Biophys Res Commun; 2013 Jul 05; 436(3):519-24. PubMed ID: 23764395
    [Abstract] [Full Text] [Related]

  • 12. Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages.
    Munn DH, McBride M, Cheung NK.
    Cancer Res; 1991 Feb 15; 51(4):1117-23. PubMed ID: 1825476
    [Abstract] [Full Text] [Related]

  • 13. Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.
    Zhang X, Olsen HS, Chen S, So E, Zhou H, Burch E, Mérigeon EY, Block DS, Strome SE.
    J Immunol; 2016 Feb 01; 196(3):1165-76. PubMed ID: 26695368
    [Abstract] [Full Text] [Related]

  • 14. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M.
    Glycobiology; 2007 Jan 01; 17(1):104-18. PubMed ID: 17012310
    [Abstract] [Full Text] [Related]

  • 15. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
    Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS.
    Mol Immunol; 2007 Mar 01; 44(7):1524-34. PubMed ID: 17045339
    [Abstract] [Full Text] [Related]

  • 16. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity.
    Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y, Kubota A, Shitara K, Nakamura K.
    Mol Immunol; 2007 May 01; 44(12):3122-31. PubMed ID: 17379311
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
    Cardarelli PM, Moldovan-Loomis MC, Preston B, Black A, Passmore D, Chen TH, Chen S, Liu J, Kuhne MR, Srinivasan M, Assad A, Witte A, Graziano RF, King DJ.
    Clin Cancer Res; 2009 May 15; 15(10):3376-83. PubMed ID: 19401346
    [Abstract] [Full Text] [Related]

  • 18. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
    Isoda Y, Yagi H, Satoh T, Shibata-Koyama M, Masuda K, Satoh M, Kato K, Iida S.
    PLoS One; 2015 May 15; 10(10):e0140120. PubMed ID: 26444434
    [Abstract] [Full Text] [Related]

  • 19. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
    Jain A, Poonia B, So EC, Vyzasatya R, Burch EE, Olsen HS, Mérigeon EY, Block DS, Zhang X, Schulze DH, Hanna NN, Twadell WS, Yfantis HG, Chan SL, Cai L, Strome SE.
    Eur J Cancer; 2013 Oct 15; 49(15):3344-52. PubMed ID: 23871153
    [Abstract] [Full Text] [Related]

  • 20. TNF receptor II fusion protein with tandemly repeated Fc domains.
    Nagashima H, Kaneko K, Yamanoi A, Motoi S, Konakahara S, Kohroki J, Masuho Y.
    J Biochem; 2011 Mar 15; 149(3):337-46. PubMed ID: 21278157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.